---
title: "Foundayo (orforglipron) in chronic weight management: Pharmacology questions"
description: "Pharmacology questions on Foundayo (orforglipron) in chronic weight management, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: Is Foundayo a GLP-1 receptor agonist? How does Foundayo work (mechanism of action)? Is Foundayo a peptide or a small molecule? How long does Foundayo stay in your system (half-life)? 3 further questions follow. 7 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/pharmacology"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Foundayo (orforglipron) in chronic weight management: Pharmacology questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Foundayo](https://uspl.lilly.com/foundayo/foundayo.html#pi)

## Mechanism

<a id="foundayo-drug-class"></a>

### Is Foundayo a GLP-1 receptor agonist?

> “FOUNDAYO™ is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=FOUNDAYO%E2%84%A2%20is%20a%20GLP%2D1%20receptor,combination%20with%20a%20reduced%2Dcalorie%20diet)

> “FOUNDAYO contains orforglipron, a GLP-1 receptor agonist.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=FOUNDAYO%20contains%20orforglipron%2C%20a%20GLP%2D1%20receptor%20agonist.)

<a id="foundayo-mechanism"></a>

### How does Foundayo work (mechanism of action)?

> “FOUNDAYO is a GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor.
>
> GLP-1 is a physiological regulator of appetite and caloric intake. GLP-1 receptors are present in brain regions that regulate appetite. In animal studies, orforglipron distributed to and activated neurons in brain regions that regulate appetite and food intake.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=FOUNDAYO%20is%20a%20GLP%2D1%20receptor,regulate%20appetite%20and%20food%20intake.)

> “FOUNDAYO reduces body weight, with greater fat mass loss than lean mass loss. FOUNDAYO decreases food intake. This effect is likely mediated by decreased appetite.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=FOUNDAYO%20reduces%20body%20weight%2C%20with,likely%20mediated%20by%20decreased%20appetite.)

> “FOUNDAYO delays gastric emptying. The delay is largest after the first dose and diminishes over time.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=FOUNDAYO%20delays%20gastric%20emptying.%20The,dose%20and%20diminishes%20over%20time.)

<a id="foundayo-small-molecule"></a>

### Is Foundayo a peptide or a small molecule?

> “A GLP-1 RA with a non-peptide, small molecule design<sup>1,2</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Once-Daily Oral GLP-1 | HCP, captured 2026-11-14](https://foundayo.lilly.com/hcp#:~:text=A%20GLP%2D1%20RA%20with%20a%20non%2Dpeptide%2C%20small%20molecule)

> “Foundayo is a small molecule, oral GLP-1 receptor agonist.<sup>1,2</sup>”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Once-Daily Oral GLP-1 | HCP, captured 2026-11-14](https://foundayo.lilly.com/hcp#:~:text=Foundayo%20is%20a%20small%20molecule%2C%20oral%20GLP%2D1%20receptor)

> “GLP-1 RA=glucagon-like peptide-1 receptor agonist”

Source: [FOUNDAYO: Foundayo™ (orforglipron) Once-Daily Oral GLP-1 | HCP, captured 2026-11-14](https://foundayo.lilly.com/hcp#:~:text=GLP%2D1%20RA%3Dglucagon%2Dlike%20peptide%2D1%20receptor%20agonist)

Note: These passages are from the home page of the Foundayo HCP site, which cites the Prescribing Information and Kawai et al., Proc Natl Acad Sci U S A 2020.

## Pharmacokinetics

<a id="foundayo-half-life"></a>

### How long does Foundayo stay in your system (half-life)?

> “The mean systemic clearance of orforglipron is 7.15 L/hour. The elimination half-life is approximately 29 to 49 hours after an oral dose.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=The%20mean%20systemic%20clearance%20of,hours%20after%20an%20oral%20dose.)

> “Steady state exposure is achieved after approximately 1 week of once daily administration.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Steady%20state%20exposure%20is%20achieved,week%20of%20once%20daily%20administration.)

<a id="foundayo-metabolism"></a>

### How is Foundayo metabolized?

> “Metabolism
>
> Orforglipron is metabolized primarily via hepatic CYP3A4 to several oxidative metabolites. These oxidative metabolites are excreted into the intestinal lumen.
>
> Excretion
>
> After administration of a single oral dose of 2.5 mg orforglipron, 87% of the dose was recovered in feces (all metabolites) and less than 1% of the dose was recovered in urine.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Metabolism,dose%20was%20recovered%20in%20urine.)

> “Orforglipron is a substrate of CYP3A4 and CYP2J2, and is not a substrate of CYP1A2, CYP2B6, CYP2C8, CYP2C19, CYP2D6, and CYP3A5.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Orforglipron%20is%20a%20substrate%20of,CYP2C8%2C%20CYP2C19%2C%20CYP2D6%2C%20and%20CYP3A5.)

<a id="foundayo-bioavailability"></a>

### What is the oral bioavailability of Foundayo?

> “Maximum concentration of orforglipron is reached 4 to 8 hours post dose. Orforglipron tablet exposure increases in a dose-proportional manner. The geometric mean absolute bioavailability of orforglipron was 77% after a 0.8 mg dose.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Maximum%20concentration%20of%20orforglipron%20is,after%20a%200.8%20mg%20dose.)

## Components

<a id="foundayo-inactive-ingredients"></a>

### What are the inactive ingredients in Foundayo?

> “Each tablet contains the following inactive ingredients: copovidone, crospovidone, magnesium stearate, microcrystalline cellulose, and sodium carbonate anhydrous. The tablet film-coating material contains polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide. Additionally, the film coating of the:
>
> 0.8 mg and 9 mg tablets contain ferric oxide red and ferric oxide yellow
> 2.5 mg and 14.5 mg tablets contain ferric oxide yellow
> 5.5 mg and 17.2 mg tablets contain ferrosoferric oxide and ferric oxide red.
>
> Each tablet contains 10 mg or less of sodium.”

Source: [FOUNDAYO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/foundayo/foundayo.html#pi:~:text=Each%20tablet%20contains%20the%20following,mg%20or%20less%20of%20sodium.)

## Related pages
- [Medical information: Foundayo (orforglipron): Chronic weight management](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management)
- [Indication](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/safety)
- [Specific populations](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/foundayo--chronic-weight-management/access-and-coverage)
